AAP: Choosing Wisely Recs on Pediatric Pulmonology, Sleep Medicine
The list, titled “Five Things Physicians and Patients Should Question,” was developed by members of the AAP Section on Pediatric Pulmonology and Sleep Medicine.
The list, titled “Five Things Physicians and Patients Should Question,” was developed by members of the AAP Section on Pediatric Pulmonology and Sleep Medicine.
Continuous positive airway pressure therapy for 6 months offers patients with obstructive sleep apnea a greater chance of reversing metabolic syndrome.
In terms of screening for obstructive sleep apnea in people living with HIV, the STOP-BANG questionnaire had good sensitivity, whereas the Berlin questionnaire and the Epworth Sleepiness Scale demonstrated good specificity.
Pitolisant may be used as an add-on therapy to continuous positive airway pressure in patients with obstructive sleep apnea suffering from residual diurnal somnolence.
The Food and Drug Administration (FDA) has expanded the approval of Inspire therapy (Inspire Medical Systems) to include patients aged 18 to 21 years with moderate to severe obstructive sleep apnea (OSA) who are unable to use continuous positive airway pressure (CPAP). Previously, the therapy was only approved for patients 22 years of age and…
VA and DoD joint guideline addresses sleep disorders in military personnel and veterans.
This slideshow reviews drug information for Sunosi. Click here for the complete Sunosi monograph.
Jazz Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor.